Top-Rated StocksTop-RatedNASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $29.77 +3.03 (+11.33%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$28.64 -1.14 (-3.81%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock About Avidity Biosciences Stock (NASDAQ:RNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avidity Biosciences alerts:Sign Up Key Stats Today's Range$26.27▼$30.6450-Day Range$26.74▼$35.1152-Week Range$21.56▼$56.00Volume3.15 million shsAverage Volume1.35 million shsMarket Capitalization$3.58 billionP/E RatioN/ADividend YieldN/APrice Target$66.69Consensus RatingBuy Company OverviewAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More… Remove Ads Avidity Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreRNA MarketRank™: Avidity Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 527th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avidity Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avidity Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.04% of the float of Avidity Biosciences has been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 4.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.04% of the float of Avidity Biosciences has been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 4.84%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.83 News SentimentAvidity Biosciences has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Avidity Biosciences this week, compared to 7 articles on an average week.Search Interest5 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows6 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,241,889.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Stock News HeadlinesAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 7,935 SharesMarch 22, 2025 | insidertrades.comAvidity Biosciences completes enrollment in Phase 1/2 Fortitude trialApril 2 at 1:35 PM | markets.businessinsider.comTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.April 3, 2025 | Priority Gold (Ad)Avidity Biosciences to Participate in Upcoming Investor ConferenceApril 1 at 9:00 AM | prnewswire.comAvidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular DystrophyMarch 31 at 9:00 AM | prnewswire.comThe Risk/Reward Of Avidity Biosciences And Its 2 Promising ProgramsMarch 26, 2025 | seekingalpha.comAvidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $979,632.40 in StockMarch 24, 2025 | americanbankingnews.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | prnewswire.comSee More Headlines RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $29.08 on January 1st, 2025. Since then, RNA stock has increased by 2.4% and is now trading at $29.77. View the best growth stocks for 2025 here. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) posted its quarterly earnings data on Thursday, February, 27th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.04. The biotechnology company had revenue of $2.97 million for the quarter, compared to the consensus estimate of $1.74 million. Avidity Biosciences had a negative net margin of 2,772.45% and a negative trailing twelve-month return on equity of 27.66%. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings2/27/2025Today4/02/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNA CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$66.69 High Stock Price Target$96.00 Low Stock Price Target$48.00 Potential Upside/Downside+124.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,772.45% Pretax Margin-2,772.45% Return on Equity-27.66% Return on Assets-24.56% Debt Debt-to-Equity RatioN/A Current Ratio17.76 Quick Ratio17.76 Sales & Book Value Annual Sales$10.90 million Price / Sales328.41 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book4.40Miscellaneous Outstanding Shares120,212,000Free Float114,918,000Market Cap$3.58 billion OptionableOptionable Beta1.02 Social Links Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:RNA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.